How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies;Comment faire le diagnostic et mieux comprendre les myopathies inflammatoires? L'utilité des auto-anticorps

Presse Medicale

Volumn 39, Issue 10, 2010, Pages 1010-1025

  Sibilia, Jean ^a,b   Chatelus, Emmanuel ^a,b   Meyer, Alain ^a,b   Gottenberg, Jacques Eric ^a,b   Sordet, Christelle ^a,b   Goetz, Joëlle ^a,b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE ANTIBODY; AUTOANTIBODY; PROTEIN CADM P140 ANTIBODY; PROTEIN EJ ANTIBODY; PROTEIN FER ANTIBODY; PROTEIN JO 1 ANTIBODY; PROTEIN JS ANTIBODY; PROTEIN KINASE C ANTIBODY; PROTEIN KJ ANTIBODY; PROTEIN KS ANTIBODY; PROTEIN KU ANTIBODY; PROTEIN MAS ANTIBODY; PROTEIN MI 2 ANTIBODY; PROTEIN MJ ANTIBODY; PROTEIN MLH1 ANTIBODY; PROTEIN OJ ANTIBODY; PROTEIN P140 ANTIBODY; PROTEIN P155 ANTIBODY; PROTEIN PL 12 ANTIBODY; PROTEIN PL 7 ANTIBODY; PROTEIN PM SCL ANTIBODY; PROTEIN PMS1 ANTIBODY; PROTEIN PMS2 ANTIBODY; PROTEIN SAE ANTIBODY; PROTEIN WA ANTIBODY; PROTEIN YRS ANTIBODY; PROTEIN ZO ANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; UNCLASSIFIED DRUG; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIGEN; CHD4 PROTEIN, HUMAN; EXORIBONUCLEASE; EXOSC10 PROTEIN, HUMAN; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX; G PROTEIN COUPLED RECEPTOR; HISTIDINE TRANSFER RNA LIGASE; HISTONE DEACETYLASE; IMMUNOLOGIC FACTOR; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1; RIBONUCLEOPROTEIN; SIGNAL RECOGNITION PARTICLE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SS-A ANTIGEN;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR DISTRIBUTION; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; HUMAN; INCLUSION BODY MYOSITIS; MYOSITIS; POLYMYOSITIS; SHORT SURVEY; ANIMAL; CLASSIFICATION; DIAGNOSTIC USE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; IMMUNODIFFUSION; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY;

AMINO ACYL-TRNA SYNTHETASES; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNOBLOTTING; IMMUNODIFFUSION; IMMUNOLOGIC FACTORS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MYOSITIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; RIBONUCLEOPROTEINS; SENSITIVITY AND SPECIFICITY; SIGNAL RECOGNITION PARTICLE; EXORIBONUCLEASES; EXOSOME MULTIENZYME RIBONUCLEASE COMPLEX;

EID: 77957368746     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.06.008     Document Type: Short Survey

References (87)

1. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
2. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
3. Hausmanowa-Petrusewicz I., Kowalska-Oledzka E., Miller F.W., Jarzabek-Chorzelska M., Targoff I.N., Blaszczyk-Kostanecka M., et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
4. Hengstman G.J., Ter Laak H.J., van Engelen B.G., van Venrooij B.G. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001, 70:706.
5. Hengstman G.J., Brouwer R., Egberts W.T., Seelig H.P., Jongen P.J., van Venrooij W.J. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002, 249:69-75.
6. Koffman B.M., Rugiero M., Dalakas M.C. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998, 21:115-117.
7. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
8. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senecal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
9. Selva-O'Callaghan A., Mijares-Boeckh-Behrens T., Labrador-Horrillos M., Solans-Laque R., Ma Grau-Junyent J., Vilardell-Tarres M. Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 2003, 42:1016-1018.
10. Casciola-Rosen L., Andrade F., Ulanet D., Wong W.B., Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815-826.
11. Nishikai M., Ohya K., Kosaka M., Akiya K., Tojo T. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. Br J Rheumatol 1998, 37:357-361.
12. Kamei H. Intracellular localization of histidyl-tRNA synthetase/Jo-1 antigen in T24 cells and some other cells. J Autoimmun 2004, 22:201-210.
13. Miller F.W., Waite K.A., Biswas T., Plotz P.H. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A 1990, 87:9933-9937.
14. Vazquez-Abad D., Rothfield N.F. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996, 39:292-296.
15. Marie I., Hachulla E., Cherin P., Dominique S., Hatron P.Y., Hellot M.F., et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002, 47:614-622.
16. Betteridge Z., Gunawardena H., North J., Slinn J., Mchugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007, 46:1005-1008.
17. Gelpi C., Kanterewicz E., Gratacos J., Targoff I.N., Rodriguez-Sanchez J.L. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996, 39:692-697.
18. Watkins J., Farzaneh-Far R., Tahir H., Wykes F., Studdy P.R., Beynon H.L. Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 2004, 43:389-390.
19. Serratrice J., Granel B., Pache X., Disdier P., De Roux-Serratrice C., Pellissier J.F., et al. A case of polymyositis with anti-histidyl-t-RNA synthetase (Jo-1) antibody syndrome following extensive vinyl chloride exposure. Clin Rheumatol 2001, 20:379-382.
20. Friedman A.W., Targoff I.N., Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26:459-467.
21. Spath M., Schroder M., Schlotter-Weigel B., Walter M.C., Hautmann H., Leinsinger G., et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004, 251:859-864.
22. Kao A.H., Lacomis D., Lucas M., Fertig N., Oddis C.V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004, 50:209-215.
23. De Bleecker J., Vervaet V., Van den Bergh P. Necrotizing myopathy with microvascular deposition of the complement membrane attack complex. Clin Neuropathol 2004, 23:76-79.
24. Miller T., Al-Lozi M.T., Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002, 73:420-428.
25. Sang Lee J., Gyu Park S., Park H., Seol W., Lee S., Kim S. Interaction network of human aminoacyl-tRNA synthetases and subunits of elongation factor 1 complex. Biochem Biophys Res Commun 2002, 291:158-164.
26. Targoff I.N., Arnett F.C., Berman L., O'Brien C., Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest 1989, 84:162-172.
27. Kajihara M., Kuwana M., Tokuda H., Yamane K., Kubo M., Hirakata M., et al. Myositis and interstitial lung disease associated with autoantibody to a transfer RNA-related protein Wa. J Rheumatol 2000, 27:2707-2710.
28. Kashiwagi M., Morgan B.A., Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 2007, 134:1571-1582.
29. Roux S., Seelig H.P., Meyer O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol 1998, 25:395-396.
30. Hengstman G.J., Vree Egberts W.T., Seelig H.P., Lundberg I.E., Moutsopoulos H.M., Doria A., et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006, 65:242-245.
31. Betteridge Z., Gunawardena H., North J., Slinn J., Mchugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007, 56:3132-3137.
32. Targoff I.N., Mamyrova G., Trieu E.P., Perurena O., Koneru B., O'Hanlon T.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
33. Kaji K., Fujimoto M., Hasegawa M., Kondo M., Saito Y., Komura K., et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007, 46:25-28.
34. Chinoy H., Fertig N., Oddis C.V., Ollier W.E., Cooper R.G. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, 66:1345-1349.
35. Gunawardena H., North J., Wedderburn L. Clinical associations of anti-p155/140 KDa in adult and juvenile dermatomyositis. Ann Rheum Dis 2007, 66(S68). Abst.
36. Gunawardena H., Wedderburn L.R., North J., Betteridge Z., Dunphy J., Chinoy H., et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008, 47:324-348.
37. Sato S., Hirakata M., Kuwana M., Suwa A., Inada S., Mimori T., et al. Autoantibodies to a 140-kd polypeptide CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005, 52:1571-1576.
38. Targoff I.N., Trieu E.P., Levy-Neto M. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 2007, 56 (Suppl):S787. Abst.
39. Casciola-Rosen L.A., Pluta A.F., Plotz P.H., Cox A.E., Morris S., Wigley F.M., et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001, 44:389-396.
40. Fujita J., Takeuchi T., Dobashi N., Ohtsuki Y., Tokuda M., Takahara J. Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis. Ann Rheum Dis 1999, 58:770-772.
41. Stuhlmuller B., Jerez R., Hausdorf G., Barthel H.R., Meurer M., Genth E., et al. Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. Arthritis Rheum 1996, 39:1860-1868.
42. Marguerie C., Bunn C.C., Copier J., Bernstein R.M., Gilroy J.M., Black C.M., et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992, 71:327-336.
43. Raijmakers R., Renz M., Wiemann C., Egberts W.V., Seelig H.P., van Venrooij W.J., et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004, 50:565-569.
44. Vandergheynst F., Ocmant A., Sordet C., Humbel R.L., Goetz J., Roufosse F., et al. Anti-pm/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol 2006, 24:129-133.
45. Franceschini F., Cavazzana I., Generali D., Quinzanini M., Viardi L., Ghirardello A., et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002, 29:1393-1397.
46. Kamei N., Yamane K., Yamashita Y., Nakanishi S., Watanabe H., Fujikawa R., et al. Anti-Ku antibody-positive scleroderma-dermatomyositis overlap syndrome developing Graves' disease and immune thrombocytopenic purpura. Intern Med 2002, 41:1199-1203.
47. Limbach F., Goetz J., Javier R.M., Kuntz J.L., Sibilia J. Signification clinique des anticorps anti-Ku. Rev Rhum Ed Fr 2000, 67 (Suppl):238. Abst.
48. Arad-Dann H., Isenberg D., Ovadia E., Shoenfeld Y., Sperling J., Sperling R. Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. J Autoimmun 1989, 2:877-888.
49. Cambridge G., Ovadia E., Isenberg D.A., Dubowitz V., Sperling J., Sperling R. Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994, 12:451-457.
50. Lundberg I., Nennesmo I., Hedfors E. A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 1992, 22:127-138.
51. Coppo P., Clauvel J.P., Bengoufa D., Oksenhendler E., Lacroix C., Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology (Oxford) 2002, 41:1040-1046.
52. Frank M.B., Mccubbin V., Trieu E., Wu Y., Isenberg D.A., Targoff I.N. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999, 12:137-142.
53. Rutjes S.A., Vree Egberts W.T., Jongen P., Van Den Hoogen F., Pruijn G.J., Van Venrooij W.J. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997, 109:32-40.
54. Brouwer R., Hengstman G.J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
55. Rhodes D.A., Ihrke G., Reinicke A.T., Malcherek G., Towey M., Isenberg D.A., et al. The 52 000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002, 106:246-256.
56. Feist E., Dorner T., Kuckelkorn U., Schmidtke G., Micheel B., Hiepe F., et al. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996, 184:1313-1318.
57. D'Cruz D., Keser G., Khamashta M.A., Direskeneli H., Targoff I.N., Miller F., et al. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol 2000, 27:161-164.
58. Suber T.L., Casciola-Rosen L., Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008, 4:201-209.
59. Nagaraju K., Casciola-Rosen L., Rosen A., Thompson C., Loeffler L., Parker T., et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 2000, 164:5459-5465.
60. Mammen A.L., Casciola-Rosen L.A., Hall J.C., Christopher-Stine L., Corse A.M., Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009, 60:3784-3793.
61. Arnett F.C., Targoff I.N., Mimori T., Goldstein R., Warner N.B., Reveille J.D. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507-1518.
62. Furuya T., Hakoda M., Tsuchiya N., Kotake S., Ichikawa N., Nanke Y., et al. Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J Rheumatol 2004, 31:1768-1774.
63. Mierau R., Dick T., Bartz-Bazzanella P., Keller E., Albert E.D., Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 39:868-876.
64. Hirakata M., Suwa A., Kuwana M., Sato S., Mimori T., Hardin J.A. Association between autoantibodies to the Ku protein and DPB1*. Arthritis Rheum 2005, 52:668-669.
65. Nagaraju K., Raben N., Loeffler L., Parker T., Rochon P.J., Lee E., et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000, 97:9209-9214.
66. Hengstman G.J., Vogels G.J., ter Laak G.J., de Witte G.J., van Engelen G.J. Myositis during long-term interferon-alpha treatment. Neurology 2000, 54:2186.
67. Allenbach Y., Solly S., Gregoire S., Dubourg O., Salomon B., Butler-Browne G., et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009, 174:989-998.
68. Stevens A.M., Sullivan K.M., Nelson J.L. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003, 42:34-39.
69. Casciola-Rosen L., Nagaraju K., Plotz P., Wang K., Levine S., Gabrielson E., et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201:591-601.
70. Blechynden L.M., Lawson M.A., Tabarias H., Garlepp M.J., Sherman J., Raben N., et al. Myositis induced by naked DNA immunization with the gene for histidyl-tRNA synthetase. Hum Gene Ther 1997, 8:1469-1480.
71. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Ronnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
72. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585.
73. Wakasugi K., Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999, 284:147-151.
74. Howard O.M., Dong H.F., Yang D., Raben N., Nagaraju K., Rosen A., et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002, 196:781-791.
75. Mathews M.B., Bernstein R.M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983, 304:177-179.
76. Fomproix N., Hernandez-Verdun D. Effects of anti-PM-Scl 100 (Rrp6p exonuclease) antibodies on prenucleolar body dynamics at the end of mitosis. Exp Cell Res 1999, 251:452-464.
77. Walker E.J., Jeffrey P.D. Sequence homology between encephalomyocarditis virus protein VPI and histidyl-tRNA synthetase supports a hypothesis of molecular mimicry in polymyositis. Med Hypotheses 1988, 25:21-25.
78. Ascherman D.P., Oriss T.B., Oddis C.V., Wright T.M. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol 2002, 169:7127-7134.
79. Tucker R.M., Roark C.L., Santiago-Raber M.L., Izui S., Kotzin B.L. Association between nuclear antigens and endogenous retrovirus in the generation of autoantibody responses in murine lupus. Arthritis Rheum 2004, 50:3626-3636.
80. Plotz P.H. Autoantibodies are anti-idiotype antibodies to antiviral antibodies. Lancet 1983, 2:824-826.
81. Okada S., Weatherhead E., Targoff I.N., Wesley R., Miller F.W. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003, 48:2285-2293.
82. Page G., Chevrel G., Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208.
83. Rosendorff A., Sakakibara S., Lu S., Kieff E., Xuan Y., DiBacco A., et al. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci U S A 2006, 103:5308-5313.
84. Levine S.M., Raben N., Xie D., Askin F.B., Tuder R., Mullins M., et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007, 56:2729-2739.
85. Amoura Z., Duhaut P., Huong D.L., Wechsler B., Costedoat-Chalumeau N., Frances C., et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005, 14:1279-1282.
86. Chinoy H., Salway F., Fertig N., Shephard N., Tait B.D., Thomson W., et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006, 8:R13.
87. O'Hanlon T.P., Carrick D.M., Targoff I.N., Arnett F.C., Reveille J.D., Carrington M., et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw. -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006, 85:111-127.